Ori Gutwerg

Ori was recently appointed Head of U.S. Generic Rx at Taro Pharmaceuticals U.S.A., Inc. Previously, Ori worked for INSUD Pharma as Vice President of Business Development and Commercial Operations, becoming the President and General Manager overseeing the new generic business unit Xiromed in March 2016. Before that, he worked for 11 years at Perrigo Pharmaceuticals in diverse roles including their R&D pipeline, finance, business development, M&A activity, supply chain and sales. Ori received a BA in communications and economics from the Tel Aviv College of Management and an MBA from Tel Aviv University and the Anderson School of Management at the University of California, Los Angeles.